Mn porphyrin-based cellular redox modulators are prospective drugs for treating brain tumors (CROSBI ID 574801)
Prilog sa skupa u zborniku | sažetak izlaganja sa skupa
Podaci o odgovornosti
Dewhirst, Mark W. ; Rajić, Zrinka ; Keir, Stephen T. ; Tovmasyan, Artak ; Spasojevic, Ivan ; Weitner, Tin ; Park, Won ; Bigner, Darell D. ; Batinic-Haberle, Ines
engleski
Mn porphyrin-based cellular redox modulators are prospective drugs for treating brain tumors
During the last two decades it became obvious that oxidative stress, the redox imbalance between cellular reactive species and endogenous antioxidant defenses, is common to numerous diseases, cancer included. For two decades we have successfully developed Mn porphyrin-based therapeutics, originally designed as SOD mimics. The ability to dismute O2.- parallels their ability to remove other major oxidizing species, peroxynitrite, ONOO-, and to modulate redox-sensitive transcriptional activity, such asHIF-1, NF-B, AP-1, and SP-1. These effects suppress excessive inflammatory and immune responses. The Mn porphyrins offer remarkable protection in many models of oxidative stress injury, such as cancer, diabetes, stroke, pain and radiation injury. Despite intensive efforts to improve multimodal treatment of brain tumors, survival remains limited. Identifying novel targeted therapies is therefore at the forefront of brain tumor research. We have recently found that a lipophilic manganese(III) meso-tetrakis(N-n-hexylpyridinium-2-yl)porphyrin, MnTnHex-2-PyP5+ , is active as a single agent in adult and pediatric glioblastoma multiforme (D-54 MG, D-245 MG, D-256 MG, D-456 MG) and pediatric medulloblastoma (D-341 MED). The effect is presumably due to the prevention of the activation of HIF-1, AP-1 and NF-B ; removal of signaling reactive species and/or oxidation of transcription factors has been suggested mechanism/s of action. Growth delays for mice bearing subcutaneous xenografts ranged from 3 (D-54 MG) to 34 days (D-341 MED). With mice bearing intracranial xenografts, MnTnHex-2-PyP5+ increased median survival by 33% (D-256 MG) and 173% (D-341 MED). We also showed that MnTnHex-2-PyP5+ significantly enhanced the radiation effects (increasing tumor growth delay for ~10 days) when given sc at 1.6 mg/kg bid over 58 days to nude mice bearing D-245 xenografts. We have recently succeeded in optimizing Mn porphyrin structure. A new drug, MnTnBuOE-2-PyP5+ has high antioxidant potency, high lipophilicity and diminished toxicity. We have found that MnTnBuOE-2-PyP5+ enhanced growth delay by 10 days when combined with radiation and temozolomide in a D-245 MG xenograft tumor line. Importantly, the compound is ~5 –fold less toxic than MnTnHex-2-PyP5+.
Mn porphyrin; brain tumor; oxidative stress; MnTnHex-2-PyP5+
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
2011.
objavljeno
Podaci o matičnoj publikaciji
From molecular information to cancer medicine
Podaci o skupu
From molecular information to cancer medicine, NCI Translational Science Meeting 2011
predavanje
28.07.2011-29.07.2011
Washington D.C., Sjedinjene Američke Države